Nashville Biosciences
  • Home
  • About
    • Meet the Team
    • Join the Team
    • Press
  • Our Work
    • Disease Cohorts
    • Product Offerings
    • Case Studies
      • Synthetic Control Arm to Boost Clinical Development
      • Measuring the Impact of New Drug Treatments
      • Improving Early-Stage Drug Discovery Process
      • Early Stage Drug Target Prioritization
      • Disease Risk Modeling
      • Pharmacovigilance
  • Contact
    • Partner with Us
  • Home
  • About
    • Meet the Team
    • Join the Team
    • Press
  • Our Work
    • Disease Cohorts
    • Product Offerings
    • Case Studies
      • Synthetic Control Arm to Boost Clinical Development
      • Measuring the Impact of New Drug Treatments
      • Improving Early-Stage Drug Discovery Process
      • Early Stage Drug Target Prioritization
      • Disease Risk Modeling
      • Pharmacovigilance
  • Contact
    • Partner with Us

Table Rocket

  • 0 Shares Share
    0
  • 0

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin eu diam lorem, id scelerisque sapien. In accumsan metus at magna vehicula placerat tempor varius ipsum. libero, non congue odio vulputate eu. Phasellus euismod magna ac est.

  • Branding
  • HTML/CSS
  • Illustration
  • Photography
A site-wide Call to Action Section! Have you fallen in love yet? Buy This Theme!

3841 Green Hills Village Dr., Suite 200
Nashville, TN 37215-2691

4660 La Jolla Village Drive
Suites 100 & 200
San Diego, California 92122

(615) 212-9625
info@nashvillebiosciences.com

LinkedIn
Twitter

Privacy Policy

© Nashville Biosciences, LLC. All Rights Reserved.

Leveraging Vanderbilt University Innovation™

WHO WE ARE

Our History

Genomics is one of the fastest developing research areas in the world today. Due to rapid advancements, in-depth genetic analysis has become essential in R&D and clinical practice.

With drug development costs forecast to double every nine years, we need more than ever to improve R&D productivity and uncover new ways to diagnose and care for diseases more efficiently. In order to increase the speed-to-market for life sciences companies, it’s imperative that we fully recognize and capture the potential of human genetics in drug and diagnostics R&D.

Button Text